VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the month of March the Company enrolled 14 patients with advanced primary, not yet treated, head and neck cancer into its global Phase III head and neck cancer trial. This marks the largest number of patients enrolled in the Company’s trial with its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) in any month to date.
Help employers find you! Check out all the jobs and post your resume.
